Direct Flow Medical, Inc. was founded with the core mission of revolutionizing the treatment of aortic and heart valve diseases. The company focuses on developing innovative medical devices, specifically the Direct Flow Medical percutaneous aortic valve. This product combines the benefits of a surgical valve with the advantages of transcatheter delivery, allowing for precise positioning, repositioning, and retrieval. Their market focus is on improving patient outcomes by minimizing risks associated with transcatheter aortic heart valve replacement (TAVR) systems.

Notable figures affiliated with Direct Flow Medical include Daniel Lemaitre, who has been featured in interviews discussing the company's impact. The company has achieved significant milestones in enhancing the safety and efficacy of TAVR procedures, reducing the risk of aortic regurgitation—a common complication. Through these advancements, Direct Flow Medical has made a substantial impact on the medical device industry, improving long-term outcomes for patients undergoing aortic valve replacement.